The vast majority of infectious organisms enter the body via the
oral and respiratory routes
Injected vaccines do not give good protection in these mucosal
sites, and so are unsuccessful in preventing access of infectious
agents to the body
Oral vaccination, in contrast, can generate protective immunity
in the gut and other mucosal sites
For oral immunisation to succeed, the vaccine delivery vehicle
is a crucial component
Proxima’s
vaccine delivery vehicle ()
is a hydrophobic carrier which targets Peyer’s patches (the
gut immune system) and generates strong immunity in the gut
Proxima’s achievements
Proof of principle with oil-based delivery system
Delivery system utilises only monographed excipients
New intellectual property protection afforded
Successful collaboration with international pharmaceutical company
Reasons for confidence in vaccine delivery
vehicle
Both local and systemic responses are observed
Delivery system enhances even above that for known mucosal immunostimulants
Applicable to a wide range of disorders – hepatitis, ‘flu,
TB, RSV and cancer
Can be applied to desensitisation – eg
allergy, diabetes, rheumatoid arthritis
Vaccine vehicle is entirely synthetic – no
reliance on live carriers
No new chemicals – readily amenable
to registration
)
is a hydrophobic carrier which targets Peyer’s patches (the
gut immune system) and generates strong immunity in the gut